UPXI vs. ADMA

Last updated Apr 1, 2026

Compare and contrast key facts about Upexi Inc. (UPXI) and ADMA Biologics, Inc. (ADMA).

Performance

UPXI vs. ADMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Upexi Inc. (UPXI) and ADMA Biologics, Inc. (ADMA). The values are adjusted to include any dividend payments, if applicable.

UPXI vs. ADMA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
UPXI Upexi Inc.	-41.33%	-52.14%	-84.87%	-61.33%	-25.37%	-28.21%
ADMA ADMA Biologics, Inc.	-50.60%	6.36%	279.42%	16.49%	175.18%	-14.55%

Fundamentals

Market Cap UPXI : $59.95M ADMA : $2.20B
EPS UPXI : -$2.35 ADMA : $0.60
PS Ratio UPXI : 2.09 ADMA : 4.34
PB Ratio UPXI : 1.23 ADMA : 4.60
Total Revenue (TTM) UPXI : $24.74M ADMA : $510.17M
Gross Profit (TTM) UPXI : $19.96M ADMA : $292.77M
EBITDA (TTM) UPXI : -$115.97M ADMA : $195.35M

Returns By Period

In the year-to-date period, UPXI achieves a -41.33% return, which is significantly higher than ADMA's -50.60% return.

UPXI

• 1D: 3.86%
• 1M: 48.64%
• YTD: -41.33%
• 6M: -82.92%
• 1Y: -52.84%
• 3Y*: -77.00%
• 5Y*: —
• 10Y*: —

ADMA

• 1D: -1.53%
• 1M: -42.13%
• YTD: -50.60%
• 6M: -38.54%
• 1Y: -54.59%
• 3Y*: 39.63%
• 5Y*: 37.55%
• 10Y*: 0.68%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

UPXI vs. ADMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

UPXI

UPXI Risk / Return Rank: 49
UPXI Sharpe Ratio Rank: 35
UPXI Sortino Ratio Rank: 83
UPXI Omega Ratio Rank: 77
UPXI Calmar Ratio Rank: 22
UPXI Martin Ratio Rank: 28

ADMA

ADMA Risk / Return Rank: 7
ADMA Sharpe Ratio Rank: 5
ADMA Sortino Ratio Rank: 7
ADMA Omega Ratio Rank: 7
ADMA Calmar Ratio Rank: 11
ADMA Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

UPXI vs. ADMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Upexi Inc. (UPXI) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	UPXI	ADMA	Difference
Sharpe ratio Return per unit of total volatility	-0.14	-0.95	+0.81
Sortino ratio Return per unit of downside risk	2.30	-1.39	+3.68
Omega ratio Gain probability vs. loss probability	1.26	0.82	+0.43
Calmar ratio Return relative to maximum drawdown	-0.58	-0.84	+0.26
Martin ratio Return relative to average drawdown	-0.81	-1.86	+1.05
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

UPXI vs. ADMA - Sharpe Ratio Comparison

The current UPXI Sharpe Ratio is -0.14, which is higher than the ADMA Sharpe Ratio of -0.95. The chart below compares the historical Sharpe Ratios of UPXI and ADMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	UPXI	ADMA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.14	-0.95	+0.81
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.63	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.01	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.30	0.01	-0.31

Correlation

The correlation between UPXI and ADMA is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

UPXI vs. ADMA - Dividend Comparison

Neither UPXI nor ADMA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

UPXI vs. ADMA - Drawdown Comparison

The maximum UPXI drawdown since its inception was -99.64%, which is greater than ADMA's maximum drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for UPXI and ADMA.

Drawdown Indicators

	UPXI	ADMA	Difference
Max Drawdown Largest peak-to-trough decline	-99.64%	-91.28%	-8.36%
Max Drawdown (1Y) Largest decline over 1 year	-96.36%	-66.18%	-30.18%
Max Drawdown (5Y) Largest decline over 5 years	—	-66.18%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-87.33%	—
Current Drawdown Current decline from peak	-99.37%	-63.24%	-36.13%
Average Drawdown Average peak-to-trough decline	-71.77%	-52.91%	-18.86%
Ulcer Index Depth and duration of drawdowns from previous peaks	68.78%	29.86%	+38.92%

Volatility

UPXI vs. ADMA - Volatility Comparison

Upexi Inc. (UPXI) has a higher volatility of 49.71% compared to ADMA Biologics, Inc. (ADMA) at 31.94%. This indicates that UPXI's price experiences larger fluctuations and is considered to be riskier than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	UPXI	ADMA	Difference
Volatility (1M) Calculated over the trailing 1-month period	49.71%	31.94%	+17.77%
Volatility (6M) Calculated over the trailing 6-month period	98.30%	44.54%	+53.76%
Volatility (1Y) Calculated over the trailing 1-year period	370.96%	57.47%	+313.49%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	207.20%	60.00%	+147.20%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	207.20%	69.12%	+138.08%

Financials